Torisel
What Torisel is used for
Renal-cell carcinoma Torisel is indicated for the first-line treatment of adult patients with advanced renal-cell carcinoma (RCC) who have at least three of six prognostic risk factors. Mantle-cell lymphoma Torisel is indicated for the treatment of adult patients with relapsed and / or refractory mantle-cell lymphoma (MCL).
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Torisel
- Active substance
- temsirolimus
- Disease area
- Carcinoma, Renal Cell; Lymphoma, Mantle-Cell
- Medicine group
- Antineoplastic agents
- ATC code
- L01XE09
- Marketing authorisation holder
- Pfizer Europe MA EEIG
- Authorised in the EU since
- 2007
Official information
In India
- Temsirolimus: 2 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Torisel used for?
Renal-cell carcinoma Torisel is indicated for the first-line treatment of adult patients with advanced renal-cell carcinoma (RCC) who have at least three of six prognostic risk factors. Mantle-cell lymphoma Torisel is indicated for the treatment of adult patients with relapsed and / or refractory mantle-cell lymphoma (MCL).
What is the active substance in Torisel?
Torisel contains temsirolimus.
Who makes Torisel?
The EU marketing authorisation holder is Pfizer Europe MA EEIG.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU